percentage of americans on glp 1 in 8 is now taking a GLP-1 medication. Yet for many patients, the conversation still begins and ends with weight loss. The future GLP-1 therapy lies in comprehensive protocols Chart: Most Americans Prefer Exercise

A small human study examining the addition of phentermine to liraglutide found no meaningful additional weight loss compared to liraglutide alone

For Lilly's Zepbound, the list price is roughly $1,100 per month, while the net price is $725

Contraindications include a history of pancreatitis or diabetic ketoacidosis, hypoglycemia, and angioedema [81]

Patient consent Written informed consent has been obtained from the patient for publication of the submitted article and accompanying images

Muscle Building with EmSculpt NEO This innovative treatment goes beyond fat reduction by simultaneously building muscle and sculpting the body, delivering visible results that diet and exercise alone cannot achieve

North America is expected to dominate the GLP-1 receptor agonist market, accounting for 40.7% of the market share in 2026